Related Experiment Video
Updated: Aug 24, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Prospective approaches to enhancing CAR T cell therapy for glioblastoma
Sun Il Choi1,2, Jinlong Yin1,2
1Henan Key Laboratory of Brain Targeted Bio-Nanomedicine, School of Life Sciences & School of Pharmacy, Henan University, Kaifeng, China.
Abstract:
Glioblastoma (GBM) is the most common malignant brain tumor. The poor clinical outcome and overall ineffectiveness of current standard treatments, including surgery, chemotherapy, and radiation, highlight the urgent need for alternative tumor-specific therapies for GBM. Chimeric antigen receptor (CAR) T cell therapy is a revolutionary therapeutic strategy for hematological malignancies, but the optimal potency of CAR T cell therapy for solid tumors, especially GBM, has not been achieved. Although CAR T cell therapeutic strategies for GBM have been assessed in clinical trials, the current antitumor activity of CAR T cells remains insufficient. In this review, we present our perspective on genetically modifying CAR constructs, overcoming T cell dysfunctions, and developing additional treatments that can improve CAR T cell effectiveness, such as functionality, persistence, and infiltration into tumor sites. Effectively improved CAR T cells may offer patients with GBM new treatment opportunities, and this review is intended to provide a comprehensive overview for researchers to develop potent CAR T cells using genetic engineering or combinatorial preparations.
Insights
Chimeric antigen receptor (CAR) T cell therapy shows promise for glioblastoma (GBM) but requires improvements. Enhancing CAR T cells through genetic engineering and combination therapies is crucial for better GBM treatment outcomes.
Area of Science:
- Neuro-oncology
- Immunotherapy
- Cancer Genetics
Background:
- Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis.
- Current treatments like surgery, chemotherapy, and radiation are largely ineffective.
- Chimeric antigen receptor (CAR) T cell therapy, successful in blood cancers, faces challenges in solid tumors like GBM.
Purpose of the Study:
- To review strategies for improving CAR T cell therapy for glioblastoma.
- To discuss genetic modifications and overcoming T cell dysfunction for enhanced efficacy.
- To explore combination treatments for better CAR T cell functionality, persistence, and tumor infiltration.
Main Methods:
- Review of existing literature and clinical trial data on CAR T cell therapy for GBM.
- Analysis of genetic engineering techniques for CAR construct optimization.
- Discussion of methods to address T cell exhaustion and tumor microenvironment barriers.
Main Results:
- CAR T cell therapy for GBM has shown limited antitumor activity in clinical trials.
- Significant challenges remain in achieving optimal potency and tumor infiltration.
- Genetic modification and combination approaches are key to enhancing CAR T cell effectiveness.
Conclusions:
- Improved CAR T cell strategies, including genetic engineering and combinatorial preparations, are essential for treating glioblastoma.
- Enhanced CAR T cells hold potential as a novel therapeutic option for GBM patients.
- Further research is needed to optimize CAR T cell therapy for solid tumors.
